Compositions and methods for treating cancer with anti-CD123 immunotherapy

US11590169B1 · kind B1 · utility

Assignee

• LENTIGEN TECHNOLOGY, INC. · US

Inventors

• Dina Schneider · Potomac, US
• Zhongyu Zhu · Frederick, US
• Florian Tomszak · Moitzfeld, DE
• Rafijul Bari · Rockville, US

Key dates

• Filing date: Mar 2, 2022
• Grant date: Feb 28, 2023
• Expiry date: Mar 2, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16043
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Chimeric antigen receptors containing CD123 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.